Role of Blood MSEPT9 in Evaluating Tumor Burden and Disease Monitoring in Colorectal Cancer Patients

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2021 Sep 30

PMID 34591323

Citations 4

Authors

Huiqin Jiang

Qian Yu

Xinning Chen

Chunyan Zhang

Junfei Shen

Minna Shen

Yihui Yang

Beili Wang

Baishen Pan

Wei Guo

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to investigate the correlation between mSEPT9 and tumor burden as well as the role of mSEPT9 in monitoring colorectal cancer (CRC) patients.

Methods: A total of 309 patients were recruited and received mSEPT9 detection in this retrospective study. Clinicopathologic characteristics were collected, including age, gender, differentiation, gene mutation, stage, and tumor markers. The correlation between mSEPT9 and clinical tumor burden was analyzed. A relative mSEPT9 value was determined using the ΔΔC method.

Results: The overall positivity rate of mSEPT9 was 39.8% in CRC patients. mSEPT9 status was significantly associated with disease status and tumor markers (CEA and CA19-9). The mSEPT9 positivity rates were 15.6%, 50.0%, 64.4%, and 70.0% for P0M0, P1M0, P0M1, and P1M1 patients, respectively (p < 0.001). Among 137 CRC patients who received mSEPT9 assay before surgery, the pre-operation mSEPT9 positivity rate increased significantly from stage I to stage IV (Stage I vs. II vs. III vs. IV 25% vs. 59.1% vs. 57.1% vs. 70.0%, respectively). Consecutive blood samples were obtained from 26 patients during therapy. The patients with increased mSEPT9 levels showed a higher progression rate.

Conclusions: mSEPT9 was a biomarker reflecting tumor burden, and serial detections of mSEPT9 could be a promising strategy for disease monitoring in CRC patients.

Citing Articles

Clinical diagnostic value of methylated SEPT9 combined with NLR, PLR and LMR in colorectal cancer.

Huang M, Deng S, Li M, Yang Z, Guo J, Deng Y BMC Gastroenterol. 2024; 24(1):240.

PMID: 39075402 PMC: 11287835. DOI: 10.1186/s12876-024-03332-6.

DNA methylation in human diseases.

Younesian S, Mohammadi M, Younesian O, Momeny M, Ghaffari S, Bashash D Heliyon. 2024; 10(11):e32366.

PMID: 38933971 PMC: 11200359. DOI: 10.1016/j.heliyon.2024.e32366.

Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.

Huang F, Yang G, Jiang H, Chen X, Yang Y, Yu Q Technol Cancer Res Treat. 2022; 21:15330338221144510.

PMID: 36573042 PMC: 9806378. DOI: 10.1177/15330338221144510.

Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.

Jiang H, Yu Q, Chen X, Zhang C, Shen J, Shen M J Clin Lab Anal. 2021; 35(11):e24030.

PMID: 34591323 PMC: 8605145. DOI: 10.1002/jcla.24030.

References

Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S . The role of SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019; 19(1):450. PMC: 6518628. DOI: 10.1186/s12885-019-5663-8. View

Young G, Symonds E, Nielsen H, Ferm L, Christensen I, Dekker E . Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer. Clin Epigenetics. 2021; 13(1):14. PMC: 7818774. DOI: 10.1186/s13148-020-00999-y. View

Warton K, Samimi G . Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015; 2:13. PMC: 4428375. DOI: 10.3389/fmolb.2015.00013. View

Snyder R, Hu C, Cuddy A, Francescatti A, Schumacher J, Van Loon K . Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. JAMA. 2018; 319(20):2104-2115. PMC: 6151863. DOI: 10.1001/jama.2018.5816. View

Luo H, Wei W, Ye Z, Zheng J, Xu R . Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med. 2021; 27(5):482-500. DOI: 10.1016/j.molmed.2020.12.011. View

Song L, Guo S, Wang J, Peng X, Jia J, Gong Y . The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med. 2018; 12(9):961-973. DOI: 10.2217/bmm-2018-0012. View

Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A . Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018; 9(1):5068. PMC: 6265251. DOI: 10.1038/s41467-018-07466-6. View

Dietrich D, Hasinger O, Liebenberg V, Field J, Kristiansen G, Soltermann A . DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 2012; 21(2):93-104. DOI: 10.1097/PDM.0b013e318240503b. View

Song L, Jia J, Yu H, Peng X, Xiao W, Gong Y . The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J Cancer Res Clin Oncol. 2017; 143(6):1093-1101. DOI: 10.1007/s00432-017-2363-0. View

10.

Morris V, Strickler J . Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annu Rev Med. 2021; 72:399-413. DOI: 10.1146/annurev-med-070119-120448. View

11.

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

12.

Bhangu J, Taghizadeh H, Braunschmid T, Bachleitner-Hofmann T, Mannhalter C . Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden. Surg Oncol. 2017; 26(4):395-401. DOI: 10.1016/j.suronc.2017.08.001. View

13.

Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W . Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68(12):2195-2205. PMC: 6872444. DOI: 10.1136/gutjnl-2019-318882. View

14.

Sameer A, Nissar S . Epigenetics in diagnosis of colorectal cancer. Mol Biol Res Commun. 2016; 5(1):49-57. PMC: 5019333. View

15.

de Vos L, Gevensleben H, Schrock A, Franzen A, Kristiansen G, Bootz F . Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clin Epigenetics. 2017; 9:125. PMC: 5709918. DOI: 10.1186/s13148-017-0425-4. View

16.

Jiang H, Yu Q, Chen X, Zhang C, Shen J, Shen M . Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients. J Clin Lab Anal. 2021; 35(11):e24030. PMC: 8605145. DOI: 10.1002/jcla.24030. View

17.

Cao F, Wei A, Hu X, He Y, Zhang J, Xia L . Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer. Clin Epigenetics. 2020; 12(1):112. PMC: 7376965. DOI: 10.1186/s13148-020-00898-2. View

18.

Wu D, Zhou G, Jin P, Zhu J, Li S, Wu Q . Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. J Mol Diagn. 2016; 18(4):535-45. DOI: 10.1016/j.jmoldx.2016.02.005. View

19.

Feng H, Jin P, Wu H . Disease prediction by cell-free DNA methylation. Brief Bioinform. 2018; 20(2):585-597. PMC: 6556903. DOI: 10.1093/bib/bby029. View

20.

Hahn O, Gronke S, Stubbs T, Ficz G, Hendrich O, Krueger F . Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biol. 2017; 18(1):56. PMC: 5370449. DOI: 10.1186/s13059-017-1187-1. View